F-plates in Iscove's modified Dulbecco's medium supplemented with 10% FCS, 5 x 10-5 M 2-ME, 1 .5 MM L-glutamine, 0 .24 MM L-asparagine, 0 .55 MM L-arginine, and antibiotics (7) . The cells were cultured at a density of 103 cells per well in the presence of serial dilutions of CSF or a highly purified standard containing 1,000 U/ml of human BSF2 (5) (kindly provided by Dr. J. van Damme, Rega Institute for Medical Research, University of Leuven, Belgium) . For the final 16 h of the 3-d culture, the cells were pulsed with 1 EICi [3H]thymidine (5 Ci/mmol). 1 U of BSF2 is defined as the amount of BSF2 that results in half-maximal thymidine incorporation in the assay. When using highly purified BSF2, the detection limit of BSF2 was found to be 0 .15 U/ml. When testing sera or CSF, the detection limit of the BSF2 assay was 10 U/ml due to negative effects of the samples when being tested at concentrations >10% . To characterize the BSF2-like activity in CSF, a neutralizing goat anti-human BSF2 antibody was used (5) (a generous gift of Dr. J . van Damme) . After a 3-h incubation of the samples with the antibody (final dilution 1 :2,000) at 37°C, the residual activity was determined in the assay.
ImmunoradiometricAssayforMurine IFN-y (MuIFN-y). MuIFN-y was measured by a solidphase, two-site "sandwich immunoassay" method (8) using the rat anti-MuIFN-y mAbs R4-6A2 and AN-18 (kindly provided by Dr. E. Havell, Trudeau Institute, Saranac Lake, NY, and Dr. S. Landolfo, University of Turin, Turin, Italy).
Human Cerebrospinal Fluids. Within the first 48 h of admission to the hospital, CSF samples were collected from 19 patients; 15 had aseptic viral meningitis and 4 had encephalitis due to HSV 1. Of these 19 patients with viral CNS disease, 9 patients were <20 yr old, 8 patients were between 20 and 40, and 2 patients were >40 yr old. Furthermore, CSF were tested from 31 patients with multiple sclerosis and from the following 16 controls, which will be collectively termed "other neurological diseases" (OND): a group of non-inflammatory diseases of the CNS, which was composed of two Alzheimer diseases, two syringomyelia, and one amyotrophic lateral sclerosis . In addition, five patients with tension headache, four with disk syndromes, and two with psychiatric disorders were included .
Results and Discussion
As shown previously, C5B1/6 mice intracerebrally infected with LCMV showed onset of meningitis 6-7 d after infection and died 6-8 h later (6) . In CSF, white blood cell pleocytosis occurred 6 d after infection, reaching 104 cells/ul on day 7 with 45% mononuclear cells . For measurement of cytokines, serum and CSF were col- lected at progressive times during infection. In the course of LCMV disease, BSF2 was first detected in serum on day 1 and in CSF on day 2 ( Fig . 1 A) . Maximum BSF2 levels were reached after rapid increase from day 4 by day 6; the concentration of BSF-2 was N60-fold higher in CSF compared with serum ( Fig. 1 A) .
In contrast to BSF2, no IFN-y was detected in the same CSF samples during the first 4 d after infection (Fig . 1 B) . After day 6 of LCMV infection (the time point pleocytosis in the CSF develops), a sharp increase in the levels of IFN-y was noted. In serum, the amount of IFN--f gradually increased between day 2 and 5 ( Fig . 1  B) . However, the levels of IFN-y were much higher in CSF compared with serum ( Fig. 1 B, Table I ).
Athymic nu/nu mice infected intracerebrally with LCMV failed to develop meningitis (9) . When assessed in ICR nu/nu mice infected with LCMV, BSF2 was only moderately increased both in serum and CSF. On day 5, the amount of BSF2 was N 160-and -340-times lower when compared with the corresponding values in CSF of C5B1/6 and ICR +/+ mice, respectively ( Fig. 1 A, Table I ). In ICR +/+ mice, maximum levels of IFN-y were usually observed on day 6 at the time of clinical signs ofmeningitis . Table I shows that in CSF of Ahymic LCMV infected ICR nu/nu mice, IFN-y remained close to baseline levels . These findings in an animal model parallel recent reports of IFN-y in human CSF during HSV1 encephalitis (10) .
In CSF of patients with infectious CNS diseases, BSF2 was found in 12 of 15 patients with aseptic viral meningitis and in all of the four patients with encephalitis due to HSV1 infection. In controls consisting of 16 patients with "other non-inflammatory neurological diseases" and of 31 patients with multiple sclerosis, BSF2 was detected only in one patient with multiple sclerosis (Fig. 2) . Antibodies against human BSF2 completely neutralized the activity detected in viral meningitis and HSV1 encephalitis (data not shown), indicating that the hybridoma growth-promoting effect in these CSF is mediated by BSF-2.
The cellular source of BSF2 in CSF is not known. Although originally described as a T cell-derived factor (4), fibroblasts, monocytes, and endothelial cells have also been found to secrete BSF2 (7, 11, 12) . In a previous study on cachectin/TNFa (a product of activated macrophages) it was not possible to identify cachectin/TNF a in CSF of mice with LCMV induced meningitis (6) . In contrast, however, cachectin/TNFa was present in CSF of patients with bacterial meningitis or of mice infected intracerebrally with Listeria monocytogenes (6) . In viral meningitis, the BSF2 in CSF of patients with aseptic viral meningitis and HSV1-induced encephalitis . discrepancy between high level of BSF2 and absence of cachectin/TNFa in CSF does not support the possibility of BSF-2 being produced independent of T cells by monocytes/macrophages in CNS. Because of concomitant production ofBSF2 and IFN-y, a T cell-derived lymphokine, one may assume that BSF2 production within the CNS may depend on local infiltrating T cells. This is further supported by the observation of only minimal synthesis of both IFN-y and BSF2 in CNS of LCMV infected athymic ICR nu/nu mice . Production of IFN-y has been shown to depend on activation of mature T cells, which are deficient in nude mice.
The findings reported in this study may help to explain the synthesis of antiviral antibodies in the CNS during viral infections (1-3) . IFN-y has been shown to synergize with IL-1 and IL-2 in antigen-specific antibody production by B lymphocytes (4) . BSF2 supports the growth of B cell hybridomas and plasmocytomas (7) and induces the final differentiation to high-rate Ig secretion of preactivated B cells (13) . Accordingly, BSF2 detected in CSF may contribute to differentiation and secretion ofantiviral antibodies by preactivated virus-specific B cells having invaded the CNS in the course of viral infection.
Summary Synthesis of B cell-stimulating factor-2 (BSF-2) and IFN-y was shown in cerebrospinal fluids (CSF) collected from mice with experimental viral meningitis . In the CSF, the level of BSF2 started to increase 24 h after intracerebral infection with lymphocytic choriomeningitis virus (LCMV) with rapid increase after day 4. IFN-y was not detected in the CSF before day 5 or 6 after infection, but increased sharply thereafter. In athymic nude mice, LCMV infection did not result in meningitis, and both BSF2 and IFN-y levels were only slightly and transiently elevated . These findings suggest that activated mature T cells are required for development of disease and production of both BSF2 and IFN-y . As observed in mice, BSF2 was also detected in 16 out of 19 CSF samples collected from patients with acute viral infections ofthe central nervous system (CNS). Intrathecal production ofBSF2 and IFN-y may be instrumental in local production of antiviral antibodies by B lymphocytes/plasma cells invading the CNS during viral CNS disease .
